Spexis (Preclinical Antibiotic Program) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Spexis (Preclinical Antibiotic Program) General Information

Description

Preclinical antibiotic program located in Allschwil, Switzerland.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Allschwil
  • Switzerland
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Basilea Pharmaceutica
Corporate Office
  • Allschwil
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spexis (Preclinical Antibiotic Program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Spexis (Preclinical Antibiotic Program)‘s full profile, request access.

Request a free trial

Spexis (Preclinical Antibiotic Program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Spexis (Preclinical Antibiotic Program)‘s full profile, request access.

Request a free trial

Spexis (Preclinical Antibiotic Program) FAQs

  • Where is Spexis (Preclinical Antibiotic Program) headquartered?

    Spexis (Preclinical Antibiotic Program) is headquartered in Allschwil, Switzerland.

  • What industry is Spexis (Preclinical Antibiotic Program) in?

    Spexis (Preclinical Antibiotic Program)’s primary industry is Buildings and Property.

  • Is Spexis (Preclinical Antibiotic Program) a private or public company?

    Spexis (Preclinical Antibiotic Program) is a Private company.

  • What is the current valuation of Spexis (Preclinical Antibiotic Program)?

    The current valuation of Spexis (Preclinical Antibiotic Program) is .

  • What is Spexis (Preclinical Antibiotic Program)’s current revenue?

    The current revenue for Spexis (Preclinical Antibiotic Program) is .

  • Who are Spexis (Preclinical Antibiotic Program)’s investors?

    Spexis has invested in Spexis (Preclinical Antibiotic Program).

  • When was Spexis (Preclinical Antibiotic Program) acquired?

    Spexis (Preclinical Antibiotic Program) was acquired on 15-Jan-2024.

  • Who acquired Spexis (Preclinical Antibiotic Program)?

    Spexis (Preclinical Antibiotic Program) was acquired by Basilea Pharmaceutica.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process